The DOI matches its Crossref record; 165 of the 167 references it cites were found in a registry or an index.
Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
Open accessAbstract
As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite this, research suggests that immunogenic cell death (ICD) induced by chemotherapy, targeted therapy, and/or radiotherapy not only leads to cancer cell death but also stimulates anti-tumor immune responses through the release of tumor neoantigens and damage-associated molecular patterns (DAMPs) (Zhai et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Zhai et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Qu, L., Li, K., Liu, K., & Hu, W. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/4959840 · Cited by 2 · cited 1×
“mentioned that the treatment of gemcitabine and oxaliplatin combined with apatinib in gallbladder cancer will significantly increase the level of humoral immune cells, and significantly decrease the levels of sIL-2R, and sICAM-1 to effectively control the progress of the disease by improving the immune function (Qu et…”
BackgroundRetractedImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 2×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 4×
“Anthracyclines can trigger exposure to CRT, as well as HSP70 and HSP90 expression, which involves translocation of these markers to the cell surface, and thus induces anti-cancer immune responses and HMGB1 release (Obeid et al., 2007; Fucikova et al., 2011).”
BackgroundInfluentialChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 2×
“The recovery of GSDME expression in tumor cells is helpful to enhance the function of immune cells to inhibit tumor growth (Wang et al., 2017).”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 2×
“ICD is a form of regulated cell death typically driven by stress (Galluzzi et al., 2017), including cell stress and cell death accompanied by exposure, active secretion, or passive release of large numbers of OPEN ACCESS”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574 · cited 1×
“Similarly, the mechanisms driving ICD have been used to produce DC-based tumor vaccines, and many clinical trials have been completed (Wculek et al., 2020).”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101 · cited 1×
“First, ICD inducers must show superior therapeutic effect when used to treat tumors in mice with normal immune function compared with those with low immune function (Vesely et al., 2011; Garg et al., 2014; Kepp et al., 2014).”
Background
Cited by
Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00515-6 · Cited by 690
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 99
Hänggi, K., Li, J., Gangadharan, A., Liu, X., Celias, D. P., Osunmakinde, O., Keske, A., Davis, J., Ahmad, F. F., Giron, A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.014 · Cited by 89
Elzoghby, A. O., Samir, O., Emam, H. E., Soliman, A., Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., & Nasr, M. L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.022 · Cited by 58
“The proteasome inhibitor bortezomib (BTZ) 41 , tyrosine kinase inhibitor crizotinib 42,43 , multi-kinase inhibitor, regorafenib 44,45 , and pyruvate kinase M2 (PKM2) inhibitor shikonin (SHK) 46,47 , are among ICD inducers 48,49 .”
BackgroundRole of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy
Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 62
“2) [34,35,42,72,75].”
Metadata
- Authors
- Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Zhang, Zhenyong
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-21
- Volume
- 14
- Pages
- 1152934-1152934
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10160433
- OpenAlex
- W4366690216
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 38 · 2023: 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- immunogenic cell death, targeted therapy, HMGB1, calreticulin, ATP, heat shock proteins, tumor immunology, chemoimmunotherapy, doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, paclitaxel, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. https://app.cochat.ai/papers/10.3389/fphar.2023.1152934
- The paper
- Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023). Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1152934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.